LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents.

Costa, Andreia / Tejpar, Sabine / Prenen, Hans / Van Cutsem, Eric

Targeted oncology

2011  Volume 6, Issue 4, Page(s) 227–233

Abstract: Currently, targeted anti-epidermal growth factor receptor (EGFR) agents have an important role ... the clinical trials findings and discusses the mechanisms and the treatment of hypomagnesaemia induced by anti-EGFR ... in the treatment of various cancers. These drugs, particularly anti-EGFR monoclonal antibodies, may induce ...

Abstract Currently, targeted anti-epidermal growth factor receptor (EGFR) agents have an important role in the treatment of various cancers. These drugs, particularly anti-EGFR monoclonal antibodies, may induce electrolyte disorders, such as hypomagnesaemia and hypocalcaemia. Early symptoms of magnesium deficiency can easily go unrecognized. However, hypomagnesaemia can in rare cases lead to serious clinical manifestations, including cardiac arrhythmias or convulsions. The elective tubular expression of renal EGF/EGFR explains the mechanism of this class-related drug side effect. Inhibition of the EGFR induces a mutated-like transient receptor potential cation channel, subfamily M, member 6 (TRPM6) syndrome, characterized by urinary magnesium and calcium wasting. The risk of hypomagnesaemia is associated with treatment duration. It is a reversible toxicity; the recovery of magnesium serum levels is usually seen 4-6 weeks of stopping the anti-EGFR antibody. Using literature from peer-reviewed journals, this review reports the clinical trials findings and discusses the mechanisms and the treatment of hypomagnesaemia induced by anti-EGFR targeted agents.
MeSH term(s) Animals ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacology ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Humans ; Magnesium/blood ; Magnesium Deficiency/blood ; Magnesium Deficiency/chemically induced ; Molecular Targeted Therapy ; Randomized Controlled Trials as Topic
Chemical Substances Antibodies, Monoclonal ; ErbB Receptors (EC 2.7.10.1) ; Magnesium (I38ZP9992A)
Language English
Publishing date 2011-11-24
Publishing country France
Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID 2222136-0
ISSN 1776-260X ; 1776-2596
ISSN (online) 1776-260X
ISSN 1776-2596
DOI 10.1007/s11523-011-0200-y
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top